<DOC>
	<DOC>NCT00395733</DOC>
	<brief_summary>The purpose of this study is to determine if the contrast agent is effective and safe in the Magnetic Resonance Imaging (MRI) of vascular diseases in patients of Chinese origin.</brief_summary>
	<brief_title>Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Vascular Diseases in Chinese Patients</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer HealthCare AG, Germany. Bayer HealthCare AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<criteria>Chinese origin Known or suspected blood vessel diseases Pregnancy Lactation Conditions interfering with MRI Allergy to any contrast agent or any drugs Participation in other trial Require emergency treatment Severely impaired liver and kidney functions</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>Gadovist</keyword>
	<keyword>Gadavist</keyword>
	<keyword>MRI Imaging</keyword>
	<keyword>vascular diseases</keyword>
	<keyword>Chinese</keyword>
</DOC>